Mave Health, a neurotech company, announced $2.1 million in seed funding led by Blume Ventures with participation from other funds and angel investors, including Stanford Angels, Dhaval Shroff, and Raymond Russell. The company recently launched a non-invasive wearable headset built to improve focus, elevate mood, and regulate stress in just 20 minutes a day.
Mave debuted with over 500 beta customers ahead of its public release last month. Based on self-reported data collected after four weeks of use:
- 80% reported productivity gains exceeding 60%
- Users reported an average mood improvement of 77%
- 75% reported stress reductions above 50%
The wearable headset supports everyday mental health and cognitive performance. Its underlying technology, transcranial direct current stimulation (tDCS), has been studied for over 25 years, with more than 10,000 published papers globally. tDCS has an excellent safety profile and is well-suited for at-home use. Mave packages this science into a lightweight, consumer-friendly device.
“The brain is the most complex system we rely on every day, and modern life is constantly overloading it. We expect it to perform at peak levels without giving it the support it needs,” said Dhawal Jain, Co-founder and CEO of Mave Health. “Instead of chasing short-term boosts that come with long-term costs, we believe in strengthening the underlying systems that drive focus, mood, and stress regulation. Our approach is to use neurotechnology that is proven to be safe, effective, and easy to use.”
